• Charting The Future Of Antimicrobial Resistance

    A conversation with Ajit Parhi, Ph.D., chief scientific officer, TAXIS Pharmaceuticals Antimicrobial resistance (AMR) poses a grave threat to global public health and is estimated to cause around 10 million deaths each year by 2050if not addressed. While U.S. government prioritization of AMR is likely [...]

  • Clinical Leader: The Rise Of Antimicrobial Resistance And Strategic Research Imperatives For 2026

    By Gregory G. Mario, MBA, president and CEO, TAXIS Pharmaceuticals The ground beneath our feet is shifting. The foundational promise of modern medicine — that bacterial infections are a solvable problem – is being severely tested by an accelerating crisis: antimicrobial resistance (AMR). 2025 brought [...]

  • ContagionLive logo

    Contagion Live: Addressing Resistance to Pathogens Like NDM-CRE Through the Lens of Antimicrobial Development

    US infections caused by NDM-producing carbapenem-resistant Enterobacterales (NDM-CRE) increased by more than 460% from 2019 to 2023, according to a Centers for Disease Control and Prevention (CDC) analysis published in Annals of Internal Medicine. CDC cautions that this surge could raise overall carbapenem-resistant Enterobacterales (CRE) infections [...]

Ready to talk?

Lorem ipsum dolor sit amet, consectetur adipisicing elit mod tempor incididunt ut labore et dolore magna aliqua.